Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters











Publication year range
1.
Probl Tuberk ; (2): 25-7, 2003.
Article in Russian | MEDLINE | ID: mdl-12790028

ABSTRACT

Based on 228 clinical cases, the authors propose procedures for complex two-stage (inpatient and outpatient) treatments of new cases of pulmonary tuberculosis by using intermittent intravenous chemotherapy that makes it possible to have a high therapeutic effect in a short space of time, to reduce the duration of hospital treatment substantially, to on the average 2-4 months, and to ensure controlled chemotherapy at the outpatient stage.


Subject(s)
Ambulatory Care/organization & administration , Patient Transfer/organization & administration , Tuberculosis, Pulmonary/therapy , Adult , Female , Humans , Length of Stay , Male , Middle Aged , Time Factors , Tuberculosis, Pulmonary/drug therapy
2.
Probl Tuberk ; (2): 27-31, 2003.
Article in Russian | MEDLINE | ID: mdl-12790029

ABSTRACT

The paper proposes the standards of combined treatment involving intermittent intravenous bactericidal chemotherapy for different groups of patients. It describes treatment regimens at the inpatient stage, defines the scope and time of control examination and correction of a treatment protocol by taking into account the pattern, phase, and dissemination of a process and the duration of the disease.


Subject(s)
Antitubercular Agents/administration & dosage , Tuberculosis, Pulmonary/drug therapy , Clinical Protocols , Combined Modality Therapy , Humans , Recurrence , Tuberculosis, Pulmonary/surgery
3.
Probl Tuberk ; (2): 33-5, 2003.
Article in Russian | MEDLINE | ID: mdl-12790031

ABSTRACT

Imozymase treatment should be started from the first hospital days in patients with destructive pulmonary tuberculosis concurrent with nonspecific purulent endobronchitis. Two-week ultrasound inhalations with imozymase in a dose of 1 ml (60 PU) may rapidly abolish not only the nonspecific inflammatory bronchial process, but also accelerate the attenuation of symptoms of intoxication, the time of abacillation, cavernous closure, and preparation for surgical interventions.


Subject(s)
Bronchitis/complications , Endopeptidases/therapeutic use , Tuberculosis, Pulmonary/complications , Tuberculosis, Pulmonary/drug therapy , Administration, Inhalation , Bacillus subtilis/chemistry , Combined Modality Therapy , Endopeptidases/chemistry , Enzymes, Immobilized/therapeutic use , Humans , Suppuration , Treatment Outcome , Tuberculosis, Pulmonary/surgery , Ultrasonic Therapy
4.
Probl Tuberk ; (4): 4-5, 1997.
Article in Russian | MEDLINE | ID: mdl-9333817

ABSTRACT

A system of in- and outpatient treatment of the first detected patients with destructive pulmonary tuberculosis is proposed. The use of various types of intravenous intermittent chemotherapy in patients with focal, infiltrative, and disseminated tuberculosis provides a high efficiency in the inpatient period (the mean time of sputum negativation is 1.6 months, that of destruction closure is 3.1 months) and early (in 2 - 3 months) transfer of these patients to outpatient additional treatment by continuing etiotropic therapy that has turned out to be effective in hospital.


Subject(s)
Ambulatory Care/organization & administration , Hospitals, Chronic Disease/organization & administration , Tuberculosis, Pulmonary/therapy , Antitubercular Agents/therapeutic use , Hospitals, Urban/organization & administration , Humans , Length of Stay , Treatment Outcome , Tuberculosis, Pulmonary/diagnosis
5.
Probl Tuberk ; (3): 22-5, 1995.
Article in Russian | MEDLINE | ID: mdl-7617627

ABSTRACT

The paper summarises the experience gained in the use of immozymase in tuberculous patients to advance the disease diagnosis and treatment. Immozymase proved valuable in obtaining sputum enriched with M. tuberculosis in patients who were previously considered noncarriers. M. tuberculosis became detectable in 28.3% of them. Immozymase instillations of the urethra before its massage for stimulation of prostatic secretion led to getting secretion in all the patients (0.35 ml, on the average). Immuzymase inhalations were used in the treatment of purulent bronchitis in patients with destructive pulmonary tuberculosis in conservative and preoperative regimens. Postoperative immozymase inhalations promoted prevention of pleuropulmonary complications. Open treatment of the caverns with immozymase after cavernotomy shortens the treatment duration. Positive results were also reached in the treatment of pleural empyema.


Subject(s)
Enzymes, Immobilized/therapeutic use , Peptide Hydrolases/therapeutic use , Tuberculosis, Pulmonary/drug therapy , Administration, Inhalation , Bronchitis/drug therapy , Empyema, Pleural/drug therapy , Enzymes, Immobilized/administration & dosage , Humans , Peptide Hydrolases/administration & dosage
6.
Probl Tuberk ; (5): 14-6, 1993.
Article in Russian | MEDLINE | ID: mdl-8295875

ABSTRACT

Recurrent tuberculosis was treated in hospital in 86 patients, 82.7% of whom had destructive disease, while 84.0% disseminated the bacteria. Combined chemotherapy included 4 tuberculostatic drugs: 10% isoniazid (7 mg/kg iv drip), streptomycin (0.5 g intramuscularly), rifadin (0.6 g orally) and tisamid (25-30 mg/kg orally). The drugs were given twice a week under the intermittent regimen in combination with 10% isoniazid (7 mg/kg) and streptomycin (0.5 g) inhalations. During a mean hospital stay of 6.5 months disappearance of destruction and discontinuation of the bacilli dissemination were achieved in 91.1% and 93.9% of patients, respectively, suffering from infiltrative and disseminated tuberculosis.


Subject(s)
Isoniazid/therapeutic use , Pyrazinamide/therapeutic use , Rifampin/therapeutic use , Streptomycin/therapeutic use , Tuberculosis, Pulmonary/drug therapy , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Recurrence , Treatment Outcome , Tuberculosis, Pulmonary/complications , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/immunology
7.
Probl Tuberk ; (1): 19-21, 1993.
Article in Russian | MEDLINE | ID: mdl-8327430

ABSTRACT

160 patients with destructive pulmonary tuberculosis of new onset were examined in a tuberculosis hospital. All of them were suspected of being ill with nonspecific bronchial disease after a questionnaire screening. Nonspecific bronchitis was diagnosed in 102 (63.7%) of them. The authors provided the criteria assessing the degree and characteristics of the bronchial tree mucous inflammation by reading endocytopulmonograms. Antituberculosis therapy combined with inhalations (including immozymase) leads to a 13% rise in the efficacy of tuberculosis treatment (cavern closure) and to a 2.5-week reduction in the terms of nonspecific bronchitis cure.


Subject(s)
Bronchitis/diagnosis , Tuberculosis, Pulmonary/diagnosis , Adult , Bronchitis/drug therapy , Bronchitis/etiology , Bronchoalveolar Lavage Fluid/cytology , Bronchoscopy , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Remission Induction , Respiratory Function Tests , Tuberculosis, Pulmonary/complications , Tuberculosis, Pulmonary/drug therapy
8.
Probl Tuberk ; (11-12): 17-9, 1992.
Article in Russian | MEDLINE | ID: mdl-1289878

ABSTRACT

Analysis of the clinical observations of 2049 patients with newly diagnosed pulmonary tuberculosis has demonstrated that 54.3% of them had the destructive phase, 52.2% bacilli excretion, 20.7% the neglected forms, and 64.3% attendant diseases. The absence of bacilli was found in 82% of the patients with the destructive forms (in 5 months' period after hospitalization), and elimination of caverns in 74.5%. The most serious defects were found in the organization of a diagnostic and therapeutic process. The complex of measures has been suggested to promote heightening of treatment effectiveness in newly detected patients at the hospital stage.


Subject(s)
Hospitalization , Tuberculosis, Pulmonary/therapy , Combined Modality Therapy , Drug Therapy, Combination , Evaluation Studies as Topic , Hospital Bed Capacity, 100 to 299 , Hospital Bed Capacity, 300 to 499 , Hospitalization/statistics & numerical data , Humans , Length of Stay/statistics & numerical data , Quality of Health Care/statistics & numerical data , Siberia , Tuberculosis, Pulmonary/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL